Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singulair gets MedWatch alert for suicide risk

Executive Summary

FDA will likely need nine months to review data potentially linking Merck's asthma treatment Singulair (motelukast) to behavior/mood changes, suicidality and suicide, the agency says in a March 27 MedWatch alert. FDA attributes the lengthy evaluation time to the complexity of the analyses. Merck updated its label four times in the past year to add post-marketing adverse events including tremor, depression, suicidality and, most recently, anxiousness

You may also be interested in...



QUOTED. 22 September 2020. Francis deSouza.

Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.

Gottlieb vs Azar vs Califf vs Gottlieb: The Public Fight Over How The US FDA Should Operate

Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.

Amgen’s KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year

Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer. 

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel